Low-cost detection of ALS biomarkers

Dr. Mohtashim Shamsi, Southern Illinois University, finalized his 2-year project with NDR. Shamsi investigated the feasibility of using label-free electrochemical detection methods to detect RAN and NfL in serum for patients with ALS. The proof-of-concept study facilitates a low cost point of care biosensing platform for clinical use. Future development of the graphene-modified low cost multiplexed wax-on-plastic biosensing chips include expanding the repertoire of ALS-associated proteins detected in the serum. The future of this technology is in stratifying patients in ALS studies to facilitate getting the right treatment to the right patient. We congratulate Dr. Shamsi on receiving a grant to continue his work on this important topic.

10 views0 comments

Recent Posts

See All

San Francisco-based Verge Genomics has begun a phase 1 human trial for its ALS drug candidate, VRG50635, that was discovered by Artificial Intelligence, AI. This novel method of discovery may speed up

NDR is pleased to announce research support for Ghada Maged for an ALS biomarkers project. Ms. Maged is currently completing an M. Sc. degree in Master of Neuroscience at Alexandria University in Egyp